stockrow
Friday 6 November 2026
Export XGN’s income statement to Excel — free account
Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024.
- Revenue
- +15.9%
- EPS
- +38.1%
- Free cash flow
- +211.3%
- Total debt
- +6.44%
Quarter to June 2026, against a year earlier
5.80
1.80
−23.68%
Follow XGN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.96 | 1.97 | 1.05 | 1.58 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
85.64 | (43.50) | (6.87) | 28.18 | |
P/B ratio |
13.90 | 7.51 | 4.96 | 9.20 | |
Price to Tangible BV |
19.96 | 10.98 | 8.02 | 16.75 | |
EV/Sales |
3.80 | 1.86 | 1.09 | 1.58 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(23.57) | (9.08) | (5.59) | (17.27) | |
EV/FCF |
(21.99) | (8.68) | (5.29) | (14.81) | |
Quick Ratio |
3.63 | 3.04 | 2.97 | 2.75 | |
Current Ratio |
4.08 | 3.45 | 3.47 | 3.18 | |
Net Debt/EBITDA |
5.07 | 1.85 | (1.56) | 0.17 | |
Debt/Assets |
39.92% | 42.86% | 47.47% | 47.09% | |
Debt/Equity |
1.38 | 1.43 | 1.71 | 2.00 | |
Asset Turnover |
1.20 | 1.30 | 1.48 | 1.29 | |
Operating CF/Net income |
(0.42) | 0.64 | 2.63 | (1.25) | |
Capex/Depreciation |
(0.27) | (0.03) | (0.16) | (0.57) | |
Interest Coverage |
(2.35) | (3.74) | (2.69) | (1.43) | |
Research and Development Expense of Revenue |
10.03% | 0.00% | 8.97% | 7.15% | |
Selling, General and Administrative Expense of Revenue |
66.37% | 74.70% | 69.72% | 62.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.44% | 4.24% | 3.78% | 4.91% | |
Graham Net Nets |
0.03 | 0.06 | 0.08 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.37%) | (15.13%) | (29.67%) | (17.42%) | |
Free Cash Flow Yield |
(4.36%) | (10.87%) | (19.73%) | (6.74%) | |
Revenue per Share |
0.75 | 0.77 | 0.73 | 0.83 | |
Operating CF per Share |
0.13 | (0.14) | (0.44) | 0.17 | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.02) | |
Free Cash Flow per Share |
0.12 | (0.14) | (0.45) | 0.14 | |
Cash per Share |
1.55 | 1.49 | 0.90 | 1.02 | |
Shareholders Equity per Share |
0.79 | 0.81 | 0.61 | 0.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.79 | 0.81 | 0.61 | 0.51 | |
Free Cash Flow |
2.67 | (3.05) | (10.64) | 3.45 | |
Working Capital |
39.70 | 34.73 | 31.02 | 29.40 | |
Capital Expenditures |
(0.27) | (0.03) | (0.23) | (0.54) | |
Net Current Asset Value |
7.90 | 8.32 | 6.06 | 3.14 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.24 | 9.35 | 15.25 | 13.34 | |
Average Payables |
2.33 | 4.15 | 4.33 | 3.47 | |
Average Assets |
53.21 | 51.36 | 46.13 | 55.35 | |
Average Common Equity |
15.50 | 13.49 | 10.42 | 16.63 |
Columns are period end dates · fundamentals updated 25 Oct 2026